Femasys Inc (FEMY)

$0.89 +0.06 (7.45%)
Market Cap 31.35M
Revenue (ttm) 1.63M
Net Income (ttm) -18.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,154.60%
Debt to Equity Ratio 0.07
Volume 2,900,210
Avg Vol 9,972,188
Day's Range N/A - N/A
Shares Out 32.58M
Stochastic %K 43%
Beta -2.55
Analysts Strong Sell
Price Target $5.67

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 770 500 3910
Fax: 404 581 5903
Address:
3950 Johns Creek Court, Suite 100, Suwanee, United States
TripTrap
TripTrap Nov. 14 at 8:24 PM
$FEMY - TODAY's Earnings Preview: What to Watch! Earnings out today Friday 11/14 after the bell Estimate is: -$0.12 EPS (minus 12 cents) What Moves Us Higher: * Beat -$0.10 or better = 20-30% pop * Revenue $700K+ (vs ~$500K expected) = Strong signal * FINALE trial update = Key catalyst *THE BIG ONE - BTD Language: BTD = Breakthrough Therapy Designation (FDA's VIP fast-track). Cuts approval timeline from 3 years to 12-18 months. Signals high probability of approval. Remember SPRB? BTD announcement = +1,378% in ONE DAY If management says ANYTHING like: "Pursuing Breakthrough Therapy Designation" "Discussions with FDA on expedited pathways" "FemBloc qualifies for fast-track designation" = IMMEDIATE 30-50% move (even without formal BTD yet) Formal BTD grant would come later as separate PR = 200-500%+ catalyst. With low retail expectations (traders jumping ship before earnings announcement) + any positive surprise = setup for explosion.
0 · Reply
TripTrap
TripTrap Nov. 14 at 8:07 PM
$FEMY - Major Holder Files 13G Hours Before Earnings!! Dauntless Investment Group just filed 13G/A showing 4.4M shares (9.99% - MAXED OUT). Why should we care? They're at the legal max they can own. Filed TODAY hours before earnings. Been aggressively adding all 2025. They own 17.5% of tradable float. Smart money doesn't: **Max out at 9.99% if bearish. **File same-day as earnings if disaster is coming. **Hold through earnings if worried. Add this to: COO timing + France order + 252% CTB + NASDAQ compliance soon to come. Dauntless Investment Group could have filed this earlier in the week...but nooo, they chose today...why? They're not exactly acting like bad news is coming hours before earnings comes outa, but will see...
2 · Reply
fernqam
fernqam Nov. 14 at 8:03 PM
$FEMY you don't have to tell us, don't care if you leave! You won't be missed!
0 · Reply
Mazen79
Mazen79 Nov. 14 at 7:41 PM
$FEMY I am out no volume
1 · Reply
Alican1994
Alican1994 Nov. 14 at 7:38 PM
$FEMY Extremely Bullish
0 · Reply
pdro1388
pdro1388 Nov. 14 at 7:27 PM
$FEMY Nice to have a 10% cushion before earnings. It usually drops, seen it over and over. Hopefully we stay on the 80s and not 50s. Sitting on big pile of shares cant wait to be rewarded big time.
0 · Reply
kjsc
kjsc Nov. 14 at 7:25 PM
$FEMY 👀
0 · Reply
TheGhost33
TheGhost33 Nov. 14 at 7:24 PM
$FEMY
0 · Reply
steve04240
steve04240 Nov. 14 at 7:18 PM
$FEMY this COULD go parabolic after hours 🤞
2 · Reply
Ked1977
Ked1977 Nov. 14 at 7:13 PM
$FEMY I have a feeling good news is going to happen in a few hours.
0 · Reply
Latest News on FEMY
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Nov 3, 2025, 8:30 AM EST - 11 days ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct 16, 2025, 9:00 AM EDT - 4 weeks ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 11, 2025, 9:00 AM EDT - 2 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep 8, 2025, 9:00 AM EDT - 2 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 25, 2025, 11:44 PM EDT - 2 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 4:05 PM EDT - 3 months ago

Femasys Announces Second Quarter Financial Results for 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Aug 6, 2025, 9:00 AM EDT - 3 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jul 1, 2025, 9:00 AM EDT - 4 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 25, 2025, 9:00 AM EDT - 5 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 17, 2025, 9:00 AM EDT - 5 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Jun 11, 2025, 9:00 AM EDT - 5 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025, 4:23 PM EDT - 6 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 5:01 PM EDT - 6 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 8 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 19, 2025, 9:20 AM EDT - 8 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 18, 2025, 9:00 AM EDT - 8 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Mar 13, 2025, 8:30 AM EDT - 8 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 25, 2025, 9:20 AM EST - 9 months ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Feb 11, 2025, 9:00 AM EST - 9 months ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 30, 2025, 8:30 AM EST - 10 months ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Jan 16, 2025, 8:30 AM EST - 10 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Mar 6, 2024, 9:00 AM EST - 1 year ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 28, 2024, 9:00 AM EST - 1 year ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Feb 6, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 26, 2024, 8:00 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Jan 23, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Dec 15, 2023, 8:30 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Nov 30, 2023, 8:30 AM EST - 2 years ago

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

TripTrap
TripTrap Nov. 14 at 8:24 PM
$FEMY - TODAY's Earnings Preview: What to Watch! Earnings out today Friday 11/14 after the bell Estimate is: -$0.12 EPS (minus 12 cents) What Moves Us Higher: * Beat -$0.10 or better = 20-30% pop * Revenue $700K+ (vs ~$500K expected) = Strong signal * FINALE trial update = Key catalyst *THE BIG ONE - BTD Language: BTD = Breakthrough Therapy Designation (FDA's VIP fast-track). Cuts approval timeline from 3 years to 12-18 months. Signals high probability of approval. Remember SPRB? BTD announcement = +1,378% in ONE DAY If management says ANYTHING like: "Pursuing Breakthrough Therapy Designation" "Discussions with FDA on expedited pathways" "FemBloc qualifies for fast-track designation" = IMMEDIATE 30-50% move (even without formal BTD yet) Formal BTD grant would come later as separate PR = 200-500%+ catalyst. With low retail expectations (traders jumping ship before earnings announcement) + any positive surprise = setup for explosion.
0 · Reply
TripTrap
TripTrap Nov. 14 at 8:07 PM
$FEMY - Major Holder Files 13G Hours Before Earnings!! Dauntless Investment Group just filed 13G/A showing 4.4M shares (9.99% - MAXED OUT). Why should we care? They're at the legal max they can own. Filed TODAY hours before earnings. Been aggressively adding all 2025. They own 17.5% of tradable float. Smart money doesn't: **Max out at 9.99% if bearish. **File same-day as earnings if disaster is coming. **Hold through earnings if worried. Add this to: COO timing + France order + 252% CTB + NASDAQ compliance soon to come. Dauntless Investment Group could have filed this earlier in the week...but nooo, they chose today...why? They're not exactly acting like bad news is coming hours before earnings comes outa, but will see...
2 · Reply
fernqam
fernqam Nov. 14 at 8:03 PM
$FEMY you don't have to tell us, don't care if you leave! You won't be missed!
0 · Reply
Mazen79
Mazen79 Nov. 14 at 7:41 PM
$FEMY I am out no volume
1 · Reply
Alican1994
Alican1994 Nov. 14 at 7:38 PM
$FEMY Extremely Bullish
0 · Reply
pdro1388
pdro1388 Nov. 14 at 7:27 PM
$FEMY Nice to have a 10% cushion before earnings. It usually drops, seen it over and over. Hopefully we stay on the 80s and not 50s. Sitting on big pile of shares cant wait to be rewarded big time.
0 · Reply
kjsc
kjsc Nov. 14 at 7:25 PM
$FEMY 👀
0 · Reply
TheGhost33
TheGhost33 Nov. 14 at 7:24 PM
$FEMY
0 · Reply
steve04240
steve04240 Nov. 14 at 7:18 PM
$FEMY this COULD go parabolic after hours 🤞
2 · Reply
Ked1977
Ked1977 Nov. 14 at 7:13 PM
$FEMY I have a feeling good news is going to happen in a few hours.
0 · Reply
Trissy08
Trissy08 Nov. 14 at 6:33 PM
$FEMY Jesus. That was prompt. I literally just sent this a couple of mins ago We’re on
1 · Reply
Trissy08
Trissy08 Nov. 14 at 6:30 PM
$FEMY we all see this sec filing today?
1 · Reply
Eduardopm
Eduardopm Nov. 14 at 6:24 PM
$FEMY someone knows something Boys This is coordinated accumulation. Retail can never never ever do these controlled dips and volatility contraction something big is coming. I’m tripling position
0 · Reply
Trissy08
Trissy08 Nov. 14 at 6:19 PM
$FEMY nice recovery today. Especially after 2 x horrendous days. For those that held. Glad you were rewarded. For those who picked up some cheapies - well done to you For those that panicked - unlucky. All joking aside. This has been a wild couple of days. Are we even sure the ER is happening tonight? Would they not have to publicly announce this and give shareholders notice ie to be able to join earnings call?
1 · Reply
longjohntrader
longjohntrader Nov. 14 at 6:14 PM
$FEMY incredibile 0.93 buyout in the making?
0 · Reply
longjohntrader
longjohntrader Nov. 14 at 6:13 PM
$FEMY i'm out....but now i think It's not the right choice
1 · Reply
GetRichorDieBuyin50
GetRichorDieBuyin50 Nov. 14 at 5:57 PM
$FEMY That filing was timed for a reason
0 · Reply
David_M_
David_M_ Nov. 14 at 5:52 PM
$FEMY
0 · Reply
CoconutNinja
CoconutNinja Nov. 14 at 5:36 PM
$FEMY I'm going to go out on a limb here. I don't think today's timing of their ER release is bearish at all. This is my thought process: 1. I've recently found out that FEMY outsources their corporate communications and related tasks to a company called Dresner. This makes sense as FEMY is still tiny and they probably don't have the expertise or staff to support these admin tasks. 2. What this means is that the release of financials is dependent on Dresner's schedule and, as a contractor/external vendor, they typically release financials (for example) in batches. 3. FEMY also has a history of releasing news/financials on odd days & odd hours so I do not see them as trying to "time the market". 4. Given the recent news on regulatory approvals and news on large deals; I expect an earnings beat today. This is just my opinion. We will find out in a few hours on how wrong I am😬
1 · Reply
4RiskyBusiness4
4RiskyBusiness4 Nov. 14 at 5:33 PM
$FEMY That’s a ton of shares available again and at a lower rate. That may explain why we’re stLling out. Shorts reloaded and can tap more.
0 · Reply
Namche
Namche Nov. 14 at 5:14 PM
$FEMY Any thoughts on earnings release being on Friday after hours? My gut says it’ll be a negative one but hoping I’m wrong with rationale being they want us to think about future growth as opposed to a bad quarter. Regardless, I’m looking for payout in Q1/Q2 2027 for my 120k shares. GLTA longs!
0 · Reply
marianochoi
marianochoi Nov. 14 at 4:24 PM
$FEMY hahaha
1 · Reply